Mupirocin

Mupirocin ointment USP, 2% is indicated for the topical treatment of impetigo due to: S. aureus and S. pyogenes.

This drug is contraindicated in individuals with a history of sensitivity reactions to any of its components.

Mupirocin ointment is not for ophthalmic use.

Drug Interactions The effect of the concurrent application of mupirocin ointment and other drug products has not been studied.

Pregnancy Teratogenic Effects Reproduction studies have been performed in rats and rabbits with mupirocin administrated subcutaneously at doses up to 22 and 43 times, respectively, the human topical dose (approximately 60 mg mupirocin per day) on a mg/m 2 basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

The following local adverse reactions have been reported in connection with the use of mupirocin ointment : Burning, stinging, or pain in 1.5% of patients; itching in 1% of patients; rash, nausea, erythema, dry skin, tenderness, swelling, contact dermatitis, and increased exudate in less than 1% of patients. Systemic reactions to mupirocin ointment have occurred rarely.